Cargando…
VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions
Sickle cell disease (SCD) results from a hemoglobin (Hb) mutation βGlu6 → βVal6 that changes normal Hb (HbA) into sickle Hb (HbS). Under hypoxia, HbS polymerizes into rigid fibers, causing red blood cells (RBCs) to sickle; leading to numerous adverse pathological effects. The RBC sickling is made wo...
Autores principales: | Abdulmalik, Osheiza, Pagare, Piyusha P., Huang, Boshi, Xu, Guoyan G., Ghatge, Mohini S., Xu, Xiaomeng, Chen, Qiukan, Anabaraonye, Nancy, Musayev, Faik N., Omar, Abdelsattar M., Venitz, Jürgen, Zhang, Yan, Safo, Martin K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679387/ https://www.ncbi.nlm.nih.gov/pubmed/33219275 http://dx.doi.org/10.1038/s41598-020-77171-2 |
Ejemplares similares
-
Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde
por: Alhashimi, Rana T., et al.
Publicado: (2023) -
Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Corrigendum
por: Abdulmalik, Osheiza, et al.
Publicado: (2011) -
Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease
por: Alhashimi, Rana T., et al.
Publicado: (2022) -
Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease
por: Ahmed, Tarek A., et al.
Publicado: (2021) -
Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease
por: Huang, Boshi, et al.
Publicado: (2022)